WO2001017509A1 - Mittel zur verbesserung und erhaltung der darmtätigkeit sowie verfahren zu dessen herstellung - Google Patents
Mittel zur verbesserung und erhaltung der darmtätigkeit sowie verfahren zu dessen herstellung Download PDFInfo
- Publication number
- WO2001017509A1 WO2001017509A1 PCT/EP2000/008645 EP0008645W WO0117509A1 WO 2001017509 A1 WO2001017509 A1 WO 2001017509A1 EP 0008645 W EP0008645 W EP 0008645W WO 0117509 A1 WO0117509 A1 WO 0117509A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intestine
- compound
- composition according
- agent according
- improving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention relates to an agent for improving and maintaining bowel activity.
- US 3,688,763 describes a method for collecting cellular material from the large intestine of humans.
- the patient swallows a capsule, the outer layer of which, together with the container underneath, dissolves in the intestine and releases a compressed sponge, which is then excreted through natural bowel evacuation.
- the sponge scrapes off the outer cells of the intestinal lumen and drags them outside.
- intestinal cells are removed from the patient in a simple manner, with the aim of subsequently examining them for tumors or cancer cells.
- This system has set itself the task of collecting intestinal cells for analysis purposes. A targeted stimulation of intestinal activity is not achieved in this way.
- a means for oral administration which consists of a container which is detachable in the stomach and releases the contents. This is filled with a substance that increases its volume in the stomach after its release, thereby suggesting a feeling of satiety in the body.
- the disadvantage of this system is that it focuses solely on filling the stomach. However, this does not stimulate intestinal activity.
- the object of the present invention is to provide an agent comprising a material which is deformable and, if appropriate, can be reduced in shape and / or reversibly compressed, which passes through the esophagus and the stomach and which has a stimulating effect on intestinal activity in the intestine.
- the agent contains a material which, if it is degradable in the stomach and / or small intestine, is provided with a compound which only dissolves in the intestine, and with active ingredients, for example for prophylaxis or with laxatives in this way is affected that these are released mainly or only in the intestine.
- the material preferably has three-dimensional polymer networks.
- the material is particularly preferably in the form of a sponge-like structure.
- sponges e.g. Gels or gel-like substances can be used.
- sponge-like structures are to be understood as foams which consist of gas-filled, spherically polyhedral cells which are delimited by highly viscous or solid cell webs. Both naturally occurring sponges and synthetically produced sponge-like structures can be used according to the invention.
- the sponge-like or -shaped structures are produced using methods known per se according to the prior art.
- a foam can be obtained in the simplest case by blowing in, by beating, shaking, spraying or stirring in the gas atmosphere in question.
- the foam structure arises due to chemical reactions. So with the polyurethanes by adding blowing agents, the decompose at a certain temperature during processing with the formation of gas, or foamed by adding liquid solvents during the polymerization. Foaming takes place either when leaving the extrusion die, ie after extrusion or injection molding, or in open molds. Hardening takes place under the conditions that are characteristic of the respective chemical compound of the material.
- the material is preferably designed such that it can be compressed to 1/2 to 1/100, preferably 1/4 to 1/50, particularly preferably 1/10 to 1/20 of its volume or size. Under physiological conditions, the compressed material should, after passage through the esophagus and stomach, preferably expand two to one hundred times, particularly preferably four to fifty times, most preferably ten to twenty times its volume in the intestine.
- the volume of the decompressed material must be selected accordingly.
- several agents according to the invention can be taken orally.
- the material used according to the invention can have any shape in the decompressed state. However, cuboid are preferred or rectangular or round configurations.
- Natural, semi-synthetic or synthetic polymers can be used as material for the preferred embodiment according to the invention as a sponge-like structure.
- suitable synthetic polymers are polyurethanes, polyacrylates, poly (meth) acrylic acid esters, homo- and copolymers of vinyl acetate.
- Natural and semi-synthetic polymers include Cellulose, cellulose ether, diethyl cellulose or cellulose esters such as cellulose diacetate, cellulose triacetate, cellulose acetate propionate, cellulose acetate and cellulose butyrate.
- Suitable according to the invention are e.g. Cellulose derivatives, especially corresponding ethers, e.g.
- natural (anionic) mucilages e.g. Xanthan gum, guar gum, tragacanth or alginic acid and salts thereof, and the like.
- insoluble polysaccharides such as chitin or chitin derivatives or microcrystalline cellulose
- Linear high molecular weight polymers are particularly preferred according to the invention. Above all, those polymers can be used according to the invention which have a fiber structure. Examples of such substances are the ski protein, such as keratins, conchagens, fibroins, elastins and collagen.
- Stably crosslinked polymers are also suitable.
- uronic acid-containing polysaccharides or their salts are conceivable, which are crosslinked by ionic bonds and are stably crosslinked by additional covalent bonds, for example ester bonds catalyzed by mineral-containing acids.
- the polymers can decompress not only in the intestine but already in the stomach and then get into the intestine in this state and pass through it.
- Suitable materials here are in particular those which are hardly noticeably or not at all degradable or resorbable in gastrointestinal liquids.
- the material contained in the agent according to the invention alone can thus already exert an effect in the intestine which is comparable to that of a fiber and on the basis of this stimulates the intestinal activity and / or contributes to the improvement and maintenance of the intestinal activity.
- the material is acted upon with active substances or laxatives in such a way that the active substances or laxatives are released predominantly or exclusively in the intestine.
- the material is provided with a compound that only dissolves in the intestine. This is particularly necessary if the material used is already degradable in the stomach or small intestine.
- the resolution of the connection is determined by various, partly also influences at the same time prevailing parameters in the intestine, such as. B. pH, pressure, redox potential and enzymatic dissolution by the intestinal flora.
- the residence time of the agent in the intestine also affects the rate at which the compound dissolves.
- the compound preferably dissolves at a pH between 5 and 10, preferably between 7 and 9, particularly preferably between 5.5 and 8.5. Dissolution in the pH environment of the intestine at a pH between 6.4 ⁇ 0.6 to 7.0 ⁇ 0.7 is most preferred.
- connection is preferably applied to the material in the form of a coating, which may also consist of can be built up several layers.
- the minimum layer thickness can vary considerably and depends on the film former used and its composition.
- Osterwald H. et al. (Acta Pharm Technol, 1980, 26: 201-209) describes, for example, a minimum layer thickness of 46 ⁇ m for the preparation of a film former in organic solvents; 161 ⁇ m layer thickness is required with ammonium salt solution, 46 ⁇ m as emulsion and 52 ⁇ m layer thickness as latex dispersion.
- the layer thickness is between 10 ⁇ m to several millimeters, preferably between 15 ⁇ m to 3 mm.
- the material can, however, also be introduced into a container which dissolves under the conditions described above.
- the container is stable in the stomach while it dissolves in the intestine.
- connection can be introduced into the material.
- This can be achieved, for example, by mixing the material with the compound during the preparation of the agent according to the invention. This can preferably also be achieved by soaking the material in a solution of the compound.
- impregnated agent can also be provided with a coating of the compound.
- the soaked material can also be introduced into the container described above.
- the material can be introduced into a container which in turn is coated or impregnated with the connection or into which the connection is introduced.
- the temporal and local resolution of the connection can be determined by the
- the solubility of the compounds can depend on one or more factors, such as pH, exposure time, redox potential of the intestine, enzymatic activities of the intestinal flora or pressure generated by the intestinal peristalsis.
- the various options for controlling the release of active substances have been described in large numbers.
- the pH-dependent solubility is described, for example, in Marvola et al., Eur J Pharm Sei, 1999, 7: 259-267 and Khan ZI et al., J Controlled Release, 1999, 58: 215-222. Pozzi F.
- HPMCP 55 Hydroxypropyl methyl cellulose phthalate
- Aqoat AS-MF hydroxypropyl methyl cellulose acetate succinate
- Aqoat AS-HF 1: 1 copolymer of methacrylic acid and ethyl acrylate (Eudragit ® L), copolymer of vinyl acetate and crotonic acid (coating CE 5142), cellulose acetate phthalate (CAP, Aquateric), methacrylate copolymers (Eudragit ® S), shellac, Time Clock System ® , Camauba wax, hydroxypropylmethyl cellulose (TC-5), Pulsincap ® , polyethylene glycol, cross-linked polyethylene glycol, Ethyl cellulose, ethyl cellulose-ethanol mixture, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, glycerol monostearate, Eudragit ® E.
- Hydrogels made from azo compounds are also possible, such as N-substituted methacrylamide, N-tert-butylacrylamide, acrylic acid in the presence of 4,4 ' - bis (methacryloylamino) - azobenzen, 4,4'-bis (N-methacryloyl-6-aminohexanoylamino) azobenzen or 3,3 ', 5,5'-tetrabromo-4,4,4', 4'-tetra ( methacryloylamino) azobenzene.
- azo compounds such as N-substituted methacrylamide, N-tert-butylacrylamide, acrylic acid in the presence of 4,4 ' - bis (methacryloylamino) - azobenzen, 4,4'-bis (N-methacryloyl-6-aminohexanoylamino) azobenzen or 3,3 ', 5,5'-tetrabromo-4,4,
- linear polymer precursors for example containing N, N-dimethylacrylamide, N-tert-butylacrylamide, acrylic acid, N-methacryloyl-glycyl-glycine-p-nitrophenyl ester, cross-linked by suitable cross-linking agents, such as N, N '- ( ⁇ -aminocaproyl) -4,4'-diaminoazobenzenes and polymers containing azo compounds, such as 2-hydroxyethyl methacrylate, 4- (methacryloyloxy) azobenzenes, N- (2-hydroxypropyl) methacrylamide copolymers, copolymers containing styrene and 2- Hydroxyethyl methacrylate crosslinked by, for example, 4,4'-divinyl azobenzene or N, N'-bis ( ⁇ -sterylsulfonyl) -4,4'-diaminoazobenzene.
- suitable cross-linking agents such as N
- poly (ether ester) azo polymers can be used according to the invention, such as, for example, copolymers containing 4- [4 - [(6-hydroxyhexyl) oxy] phenyl] azobenzoic acid and 16-hydroxyhexadecanoic acid, copolymers containing 4- [2- [2 - (2-hydroxyethoxy) - ethoxy] ethoxy] benzoic acid, 4- [4- [2- [2- (2-hydroxyethoxy) ethoxy] ethoxy] - phenyljazobenzoic acid and 16-hydroxyhexadecanoic acid or 12- Hydroxydodecanoic acid and segmented polyurethanes containing m-xylene diisocyanate, 3,3'-dihydroxyazobenzene, polyethylene glycol or 1,2-propanediol.
- Azo compounds containing polyamides or copolymers of 4- [4- (chlorocarbonyl) phenyl)] azobenzoyl chloride and ⁇ , ⁇ -bis (aminopropyl) poly (tetramethylene oxide) and copolymers of 4- [4- (chlorocarbonyl) phenyl] azobenzoyl chloride can also be used and Jeffamine ED-600.
- pectins are used which can also be coated or embedded in a matrix, such as methoxy pectin, amidated pectin, calcium pectinate, pectin in combination with ethyl cellulose (Aquacoat, Surelease), acrylic acid ester polymers (Eudragit RS30D, Eudragit NE30D). Combinations of pectins with other fibers are also used. Examples of fiber are guar (galactomannan) or chitosan, where the fiber itself can in turn be coated or be part of a matrix.
- film formers polymethacrylate solutions, copolymers containing polyurethane and di-, oligo- or polysaccharides (galactomannans) and ethylgalactomannans or acetylgalactomannans. Also find cyanoacrylate, inulin, inulin suspensions with Eudragit-RS, methacrylated inulin, chondroitin sulfate, chondroitin polymers containing 1, 12-diaminododecane and
- Dicyclohexylcarbodiimide, amorphous amylose or amorphous amylose are used together with other film-forming polymers as film formers.
- Dextrans can also be used, which can be crosslinked in various ways, for example with diisocyanates, fatty acid esters, for example lauric acid, glutaraldehyde.
- Conjugates of biphenylacetic acid and ⁇ -cyclodextrin, copolymers of ⁇ -cyclodextrins with methacrylic acid copolymers or acrylic acid polymers with disaccharide side groups are also used according to the invention.
- the selection of the connections as well as their diverse Combination options enable targeted temporal and local control of the release of the material in the intestine.
- the compound can also already contain active ingredients and / or laxatives.
- the application of active substances or laxatives to the material contained in the agent according to the invention can be carried out in a comparable manner to that described above when the compound was applied to the material.
- the active ingredients or laxatives or combinations thereof can be applied / applied to the material. This can preferably be done in the form of a coating, the coating optionally also being composed of several layers.
- the active ingredients and / or laxatives can be incorporated into the material. This can be achieved, for example, by directly mixing the material with the active ingredients and / or laxatives in the preparation of the agents according to the invention. This can preferably also be achieved by soaking the material in a solution of the active ingredients and / or laxatives.
- a solution of the active ingredients and / or laxatives e.g.
- impregnated material can also be provided with a coating of the active ingredients and / or laxatives.
- the material can also be encased with the active ingredients and / or laxatives in the form of a container. Furthermore, the material can be introduced into a container, for example from the aforementioned compounds, which in turn is coated or soaked with the active substances and / or laxatives or into which the active substances and / or laxatives are introduced.
- the material thus acted upon with the active substances and / or laxatives can be compressed and additionally provided with a connection of the type described above and in the manner already mentioned.
- the connection in the intestine leads to decompression of the material obtained in this way in the intestine, combined with the release of the active substances and / or laxatives.
- the active substances and / or laxatives themselves can be provided with the compounds of the type described above and in the manner already mentioned.
- the active ingredients and / or laxatives thus obtained can then be applied to the material in the manner described.
- the material loaded with the active substances and / or laxatives is compressed and, if necessary, additionally provided with a compound that only dissolves in the intestine.
- the active substances and / or laxatives are released by dissolving the compound.
- Active substances in the sense of the invention are understood to mean all substances with a pharmaceutical or biological effect.
- Examples are betamethasone, thioetic acid, sotalol, salbutamol, norfenefrin, solymarin, dihydroergotamine, buflumedil, etofibrate, indomethacin, oxazepam, beta-acetyldigoxim, piroxicam, haloperidol, ISMN, amitirptylin, diflipinolinol, diclipinolinol, diclipinolinol, diclipinolinol, diclipinolinin, diclipinolinin, diclipinolinacin Methylprednisolone, clonidine, fenofibrate, allopurinol, pirenzepin, levothyroxine, tamoxifen, metildigoxin, o- (beta-hydroxyethyl) ruto
- Etofyllinclofibrat Vincamin, Cinarizin, Diazepam, Ketoprofen, Flupentixol, Molsidomin, Glibornuid, Dimetinden, Melperon, Soquinolol, Dibydrocodein, Clomethiazol, Clemastin, Glisoxepid, Kallidinogenase, Oxyfedrin, Baclacinin, Carboxin, Carbox Prenylamine, salazosulfapyridine, astemizole, sulpiride, benzerazide, dibenzepine, acetylsalicylic acid, miconazole, nystatin, ketone conazole, Na picosulfate, colesty ramin, gemifibrocil, rifampicin, fluorocortolon, mexiletine, amoxadrinolin
- Mucopolysaccharide polysulfuric acid ester triazolam, mianserin, tiaprofenic acid, amezinium metal sulfate, mefloquine, probucol, quinidine, carbamepine, Mg-L-aspartate, penbutolol, piretanide, amitriptyline, cyproterone, Na-valpropinate, modeverinic acid, mebeverinic acid , Phenprocoumon, amantadine, naproxen, cartelol, famotidine, methyldopa, auranofin, estriol, nadolol, levomepromazine, doxorubicin, medofenoxate, azathioprine, flutamide, norfloxacin, fendiline, prajmalium bitartrate, aescin.
- acetaminophen paracetamol
- acetohexamide acetyldigoxime
- acetylsalicylic acid acromycin
- anipamil benzocaine
- beta-carotene beta-carotene
- choramphenicol chlordiazepoxide
- chlormadinoacetate chlorthiazid
- cinnarizine donazepamethonone
- clonazepamoxinone clonazepamoxinone
- clonazepamoxinone clonazepamoxinone
- clonazepamoxinone clonazepamoxinone
- Digoxin dihydroergotamine, drotaverine, flunitrazepam, furosemide, gramicidin, griseofluvin, hexobarbital, hydrochlorothiazide, hydrocortisone, hydroflumethazig, indi
- active substances in the sense of the invention are also to be understood as laxatives.
- the agent according to the invention can also be foodstuffs or food supplements, e.g. Contain vitamins, fiber, proteins or minerals as well as other food substances, stimulants or flavorings.
- auxiliary substances can also be added to the material. This could also include antioxidants, preservatives, colors or sweeteners. Among other things, retarding substances can also be considered if pharmaceutically active substances are used.
- agents according to the present invention can additionally contain fillers, disintegrants, binders and lubricants as well as carriers.
- Essentially water-insoluble can be used as retarding auxiliaries
- lipids including fatty alcohols, for example cetyl alcohol, stearyl alcohol and cetostearyl alcohol; Glycerides, e.g. Glycerol monostearate or mixtures of mono-, di- and triglycerides of vegetable oils; hydrogenated oils such as hydrogenated castor oil or hydrogenated cottonseed oil; Waxes, for example beeswax or camauba wax; solid hydrocarbons, eg paraffin or earth wax; Fatty acids, eg stearic acid; certain cellulose derivatives, for example ethyl cellulose or acetyl cellulose; Polymers or copolymers, such as polyalkylenes, for example polyethylene, polyvinyl compounds, for example polyvinyl chloride or polyvinyl acetate, and also vinyl chloride-vinyl acetate copolymers and copolymers with crotonic acid, or polymers and copolymers of acrylates and methacrylates
- the present invention further relates to an agent for use in improving and maintaining bowel function and in improving and / or normalizing bowel movements, which contains a material which, if it is degradable in the stomach and / or small intestine, is provided with a compound which only dissolves in the intestine and is acted upon with active ingredients, for example for prophylaxis or with laxatives, in such a way that these are released predominantly or only in the intestine.
- the present invention also relates to a process for the preparation of the agent described above.
- a suspension of the material is first produced and then freeze-dried. If necessary, the material is first crushed and / or subjected to an alkaline and / or an acid pretreatment. Freeze-drying is preferably carried out at - 80 to + 50 ° C, in particular at -30 to + 40 ° C.
- soluble collagen from the skins of young cattle or pigs (animals) can be used, for example.
- the soluble collagen components in the skin of animals decrease with age of the organism, since the collagen forms an insoluble three-dimensional network through intermolecular cross-linking.
- the cross-linking points are solid chemical bonds between individual collagen molecules.
- the preparation according to the invention is particularly preferably carried out as follows: First, a suspension of the material is produced and a sponge-like or foam-like structure is produced from this suspension according to methods known per se. Then that will
- connection applied and / or a connection introduced into the material and / or this material enveloped with such a connection, this connection only dissolving in the intestine.
- the material can additionally contain the above-mentioned compounds, pharmaceutically and / or biologically active substances, foods or nutritional supplements,
- Food substances, stimulants, flavorings, auxiliary substances or retarding substances are applied.
- the compressed material thus produced can be encased with the compound described above. That is, either the container becomes a container, e.g. a capsule shell, produced and the material introduced into this. Or the connection is applied directly to the material, for example by dipping, spraying, brushing or similar methods. In another embodiment of the invention, the connection is introduced into the material. This can e.g. can be achieved by watering.
- the invention is not limited to the methods described, but also applies to all other methods in which sponges, sponge-like structures or gels are produced which, due to the relative insolubility in water and / or gastrointestinal fluids, optionally mediated by correspondingly suitable compounds should or can achieve long-term stimulation of bowel activity.
- the purpose of the method according to the invention is to obtain an agent which has a long-lasting stimulating effect in the intestine and at the same time is suitable for the targeted release of active substances, in particular for prophylaxis or laxatives in the intestine. This goal is achieved with the process steps mentioned.
- the agent according to the invention is taken orally.
- the solid, compressed sponge or solid foam body passes through the mouth, throat, esophagus and stomach by adding drinking liquid as well as slight chewing or swallowing movements and preferably rinses back to its original volume in the intestine. If necessary, the volume can also be larger or smaller than the original one.
- the polymer consisting of natural, semi-synthetic or synthetic as well as stably cross-linked polymer retains as described Material, especially in the form of a solid sponge or foam body due to its predominantly three-dimensional polymer network and the poor solubility in the intestine over several hours, its originally existing solid and mechanically stable structure.
- the agent according to the invention is present in a sufficiently compressed form when it passes through the esophagus and when it passes through the stomach or small intestine in order to decompress in the intestine, in particular in the large intestine, and to develop the desired stimulating effect.
- the agent can also decompress in the stomach and in this state get into the intestine and pass through it. This is particularly true for materials that can pass through the stomach and small intestine even in decompressed form without being broken down.
- stomach or small intestine begins, appropriate protection against premature degradation must be provided.
- Such protection can achieved that the material is provided with a compound that only dissolves in the intestine.
- this connection can be introduced into / onto the material in the manner already mentioned above, or can be encased with it.
- agent according to the invention can optionally be provided, so to speak, with a previously mentioned connection.
- the oral intake of the agent according to the invention and the decompression in the intestine stimulate the stretch receptors of the intestinal wall, which in turn trigger contractions of the intestine.
- long-term stimulation of intestinal activity can be achieved, resulting in a shortening of the passage time of the intestinal contents and in connection with an improved water-binding capacity of the stool followed by more favorable growth conditions of the intestinal flora, which ultimately stimulates the intestinal secretion and intestinal blood flow.
- the intestinal activity can also be improved and maintained by the release of the active ingredients or laxatives. In addition, however, active substances can also be released in the intestine, which develop their effect in a place other than the intestine.
- the present invention relates to the use of the agent according to the invention for the production of agents for improving and maintaining bowel activity and for improving and / or normalizing bowel movements and for the production of pharmaceutically active agents and / or foods and / or nutritional supplements and / or (diet) -Nahrungsstoffn.
- the agent according to the invention itself can be used to improve and maintain intestinal activity and to improve and / or normalize bowel movements and / or to shorten the passage time of the food in the intestine, combined with a prophylactic or laxative effect.
- the agent according to the invention is used in the fields of pharmacy and / or health care and / or for nutrition and / or
- the agent contains the active ingredients or foodstuffs, food supplements, foodstuffs, stimulants, flavorings or other auxiliaries already described above.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00960602A EP1210071A1 (de) | 1999-09-06 | 2000-09-05 | Mittel zur verbesserung und erhaltung der darmtätigkeit sowie verfahren zu dessen herstellung |
CA002384046A CA2384046A1 (en) | 1999-09-06 | 2000-09-05 | Method for improving and maintaining bowel function as well as a method for the production thereof |
AU72843/00A AU7284300A (en) | 1999-09-06 | 2000-09-05 | Method for improving and maintaining bowel function as well as a method for the production thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE29915668U DE29915668U1 (de) | 1999-09-06 | 1999-09-06 | Mittel zur Verbesserung und Erhaltung der Darmtätigkeit |
DE29915668.0 | 1999-09-06 | ||
DE1999142424 DE19942424A1 (de) | 1999-09-06 | 1999-09-06 | Mittel zur Verbesserung und Erhaltung der Darmtätigkeit sowie Verfahren zu dessen Herstellung |
DE19942424.1 | 1999-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001017509A1 true WO2001017509A1 (de) | 2001-03-15 |
Family
ID=26054843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/008645 WO2001017509A1 (de) | 1999-09-06 | 2000-09-05 | Mittel zur verbesserung und erhaltung der darmtätigkeit sowie verfahren zu dessen herstellung |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1210071A1 (de) |
AU (1) | AU7284300A (de) |
CA (1) | CA2384046A1 (de) |
WO (1) | WO2001017509A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004032926A1 (en) * | 2002-10-09 | 2004-04-22 | Keiser Dale A | Gelled laxative compositions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6032438B2 (ja) * | 2011-10-11 | 2016-11-30 | 日産化学工業株式会社 | 硬化膜形成組成物、配向材および位相差材 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3688763A (en) * | 1969-07-28 | 1972-09-05 | Raymond Cromarty | Diagnostic device and method |
US4871549A (en) * | 1985-07-19 | 1989-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Time-controlled explosion systems and processes for preparing the same |
WO1998009617A1 (de) * | 1996-09-07 | 1998-03-12 | Beisel Guenther | Mittel mit retardwirkung |
WO1998023259A1 (de) * | 1996-11-27 | 1998-06-04 | Beisel Guenther | Mittel zur erzeugung eines langanhaltenden sättigungseffekts |
WO1998026767A2 (en) * | 1996-12-17 | 1998-06-25 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
EP0901792A1 (de) * | 1997-09-05 | 1999-03-17 | Dr. Suwelack Skin & Health Care AG | Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung |
DE29915656U1 (de) * | 1999-09-06 | 2000-04-20 | Beisel Guenther | Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts |
DE29915634U1 (de) * | 1999-09-06 | 2000-05-25 | Beisel Guenther | Mittel zur Stimulanz der Darmtätigkeit |
-
2000
- 2000-09-05 AU AU72843/00A patent/AU7284300A/en not_active Abandoned
- 2000-09-05 WO PCT/EP2000/008645 patent/WO2001017509A1/de not_active Application Discontinuation
- 2000-09-05 CA CA002384046A patent/CA2384046A1/en not_active Abandoned
- 2000-09-05 EP EP00960602A patent/EP1210071A1/de not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3688763A (en) * | 1969-07-28 | 1972-09-05 | Raymond Cromarty | Diagnostic device and method |
US4871549A (en) * | 1985-07-19 | 1989-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Time-controlled explosion systems and processes for preparing the same |
WO1998009617A1 (de) * | 1996-09-07 | 1998-03-12 | Beisel Guenther | Mittel mit retardwirkung |
WO1998023259A1 (de) * | 1996-11-27 | 1998-06-04 | Beisel Guenther | Mittel zur erzeugung eines langanhaltenden sättigungseffekts |
WO1998026767A2 (en) * | 1996-12-17 | 1998-06-25 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
EP0901792A1 (de) * | 1997-09-05 | 1999-03-17 | Dr. Suwelack Skin & Health Care AG | Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung |
DE29915656U1 (de) * | 1999-09-06 | 2000-04-20 | Beisel Guenther | Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts |
DE29915634U1 (de) * | 1999-09-06 | 2000-05-25 | Beisel Guenther | Mittel zur Stimulanz der Darmtätigkeit |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004032926A1 (en) * | 2002-10-09 | 2004-04-22 | Keiser Dale A | Gelled laxative compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1210071A1 (de) | 2002-06-05 |
CA2384046A1 (en) | 2001-03-15 |
AU7284300A (en) | 2001-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6677318B1 (en) | Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said | |
DE60120413T2 (de) | Quervernetzte stark amylose haltige stärke zur verwendung in pharmazeutischen formulierungen mit kontrollierter freisetzung und verfahren zu ihrer herstellung | |
EP0756480B1 (de) | Retard-matrixpellets und verfahren zu ihrer herstellung | |
DE60225178T2 (de) | Auf in vivo abbaubaren und quellbaren modifizierten dextranhydrogelen basierende systeme zur stossweisen freisetzung biologisch aktiver stoffe | |
EP1209988B1 (de) | Vernetztes mittel zur erzeugung eines langanhaltenden sättigungseffekts und verfahren zu dessen herstellung | |
EP0948316B1 (de) | Mittel zur erzeugung eines langanhaltenden sättigungseffekts | |
DE19942417A1 (de) | Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts und Verfahren zu dessen Herstellung | |
EP0936903B1 (de) | Mittel mit retardwirkung | |
WO2001017509A1 (de) | Mittel zur verbesserung und erhaltung der darmtätigkeit sowie verfahren zu dessen herstellung | |
DE60214154T2 (de) | Pharmazeutisches freigabekonstrukt zur magenretention | |
DE19942424A1 (de) | Mittel zur Verbesserung und Erhaltung der Darmtätigkeit sowie Verfahren zu dessen Herstellung | |
Alpizar-Reyes et al. | Recent approaches in alginate-based carriers for delivery of therapeutics and biomedicine | |
DE10259505A1 (de) | Verfahren zur Herstellung von schwammartigen Materialien | |
DE10016356B4 (de) | Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung | |
WO2004056908A2 (de) | Verfahren zur herstellung von schwammartigen materialien | |
WO2001017510A1 (de) | Mittel zur stimulanz der darmtätigkeit sowie verfahren zu dessen herstellung | |
DE19942365A1 (de) | Mittel zur Stimulanz der Darmtätigkeit sowie Verfahren zu dessen Herstellung | |
Gayakwad et al. | Natural Polymers In The Development Of Gastroretentive Systems: A Review | |
Hamman | Development of multiple-unit pellet systems by employing the SeDeM expert diagram system | |
DE10247910A1 (de) | Mittel zur Erzeugung eines langanhaltenden Sättigungseffektes | |
Sharma et al. | A Comprehensive Review of Disintegrants: Backbone of disintegration | |
DE10259508A1 (de) | Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung | |
DE10259504A1 (de) | Verfahren zur Herstellung eines oral einnehmbaren Mittels enthaltend schwammartige Materialien | |
EP1450763B1 (de) | Mittel zur behandlung von übergewicht in kombination mit weiteren indikationen | |
DE102010026090A1 (de) | Sublinguale Darreichungsform auf der Basis von extrudiertem Gummi Arabicum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000960602 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2384046 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2000960602 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10070672 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000960602 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |